Androgen deprivation therapy (ADT) is a common treatment option for men with biochemical relapse from prostate cancer. ADT is associated with changes in mood, cognition and quality of life, and most recently with increased risk for Alzheimer’s disease (AD). This study examined changes in brain metabolism using positron emission tomography (PET) in men undergoing intermittent ADT. Refer to the following published article for more information on the larger study. This page is a sub-set of participants from the larger study. Cherrier, M. M., S. Aubin and C. S. Higano (2009). "Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer." Psychooncology 18(3): 237-247. If you wish to access any data, please complete the data use agreement form, found under materials and send a complete, signed copy of the form to cherrier@uw.edu and you will be given viewing access to the data components of this site.